Dishman Pharma's subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company.
The acquisition, he says, is funded trough internal accruals. Below is the edited transcript of his interview with CNBC-TV18's Reema Tendulkar. Also watch the accompanying video. Q: Could you tell us about this acquisition of Creapharm Parenterals that you have done? A: This is a small R&D formulation development company. They will make supplies to clinical phases 1, 2, 3. The company is based in France. We acquired this to help our R&D to develop formulations also, to make supplies to clinical phase 1, 2, 3. Right now, our Carbogen Amcis is making some development formulations for some customers. Up to lab scale, we are almost complete. Now, we make a facility to make supplies to clinical phase 1, 2, 3. ThatDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
